ANTI-SARS-COV-2 VACCINATION: ABOUT THE ALGERIAN EXPERIENCE

##plugins.themes.bootstrap3.article.sidebar##

PDF
Published Aug 5, 2023
DOI https://doi.org/10.20428/yjms.v17i1.2124

##plugins.themes.bootstrap3.article.main##

Imene ADOUANI
Department of pharmacy, Faculty of medicine, University of Ferhat Abbas Setif-1, Setif, Algeria : Laboratory of biotechnology and genomics in medical sciences, Setif, Algeria
Zineb BENZAOUI
Department of pharmacy, Faculty of medicine, University of Ferhat Abbas Setif-1, Setif, Algeria
Nacira BOULAACHEB
Department of pharmacy, Faculty of medicine, University of Ferhat Abbas Setif-1, Setif, Algeria : Laboratory of urban projects, cities and territories, Setif, Algeria

Abstract

Introduction: The recent pandemic of the novel coronavirus-2 of severe acute respiratory syndrome (SARS-Cov-2 or
COVID-19), is one of the deadly diseases of the last twenty years.
Objectives: Many efforts have been devoted to find solutions to fight COVID-19 pandemic as quickly and effectively as
possible. After the development of COVID-19 vaccines, several rumors about their effectiveness and safety spread all over
the world. The objective of the present study is to report data about the vaccination in Algeria and to document the various
side-effects notified by the Algerian population during the 24 hours following the administration of anti-COVID-19
vaccines.
Methods: An online observational retrospective survey targeting Algerian adults residing in the different Wilayas of the
country has been conducted.
Results: Nine hundred and ninety-four (994) Algerians participated in this survey. The age of the participants ranged
between 18 and 78 years with an average of 34.75 ± 14.31 years. The sex ratio was 2.1 with female predominance. The
participants were from different Wilayas (provinces) especially: Bejaia (21.6%), Setif (17.8%), Algiers (8.5%), Batna
(4.9%), etc. Almost half of the participants (46.9%) have a university degree. A total of 24% of participants were
vaccinated between February 2021 and March 2022. Of these, 81.1% were fully vaccinated and 18.9% were partially
vaccinated. Numerous vaccines were administered; Sinovac (50.4%), Janssen (16%), Sputnik (12.2%), AstraZeneca
(10.1%), Sinopharm (5.9%), Pfizer (4.6%). More than half (62.3%) did not feel any signs after vaccination. Others (37.7%)
claimed the appearance of certain effects including fever (21.6%), pain (16.5%), asthenia (8.1%), headache (7.2%) and
others (40.1%).
Conclusion: According to the Algerian experience, in the majority of cases, anti-COVID-19 vaccines are devoid from
annoying effects. In some cases, it may be accompanied by some mild effects. However, vaccination is an important way
to prevent COVID-19 infection and the vaccine can be used safely.

Downloads

Download data is not yet available.

##plugins.themes.bootstrap3.article.details##

Keywords

Algeria; Anti-COVID-19 vaccines; Pharmacovigilance; Side-effects; Survey.

Issue
Vol. 17 No. 1 (2023)
Section
Original Article
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

YJMS publishes Open Access articles under the Creative Commons Attribution (CC BY) license. If author(s) submit their manuscript for consideration by YJMS, they agree to have the CC BY license applied to their work, which means that it may be reused in any form provided that the author(s) and the journal are properly cited. Under this license, author(s) also preserve the right of reusing the content of their manuscript provided that they cite the YJMS.